Bliss GVS Pharma share news, announcements and annual reports
NSE: BLISSGVSBSE: 506197Pharmaceuticals & BiotechnologySmall Cap
Bliss GVS Pharma Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Oct 1985 on BSE, Jul 2010 on NSE
Last close ₹680.90up ₹32.40 (5.00%)BSE ₹682.50
Share price at the NSE close on 29 Oct 2026. Previous close ₹648.50.
29 Oct: open ₹667.95, high ₹680.90, low ₹652.75
52-week range of traded prices to 29 Oct 2026
₹118.00Low, 10 Nov 2025₹739.90High, 28 Sep 2026
- Under NSE's long-term additional surveillance, stage IV, on the list for 29 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Delivery only: shares bought must be paid for in full, with no selling on the same day.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹7,240 Cr1,000th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 44.92
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 5.61
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.22%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 13.3%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 14.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day. Volume in the glossary
- 4,47,694
Bliss GVS Pharma disputes and clarifications
24 filed, newest first.
Oct 2025
Jul 2025
May 2025
Apr 2025
Nov 2024
Jul 2023
20 Jul · Legal
The exchange asked on 18 Jul 2023
Nov 2022
30 Nov · Legal
29 Nov · Legal
Exchange has sought clarification from Bliss GVS Pharma Limited with respect to Financial Results dated 07-Nov-2022 for the period Sep, 2022On the basis of aforesaid disclosure, the Listed entity is required to clarify the following:Standalone & Consolidated: Cash FlowThe response of the company is awaited
Apr 2021
1 Apr · Legal
The exchange asked on 31 Mar 2021
Mar 2021
17 Mar · Legal
The exchange asked on 17 Mar 2021
Mar 2020
Oct 2019
24 Oct · Legal
The exchange asked on 23 Oct 2019
Aug 2019
27 Aug · Legal
The exchange asked on 23 Aug 2019
5 Aug · Legal
Significant movement in price has been observed in Bliss GVS Pharma Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written to the company. The response from the company is awaited.
Mar 2019
9 Mar · Legal
Exchange has sought clarification from Bliss GVS Pharma Limited with respect to announcement dated 25-Feb-2019, regarding " Bliss GVS Pharma Limited has informed the Exchange regarding Board meeting held on February 25, 2019.". On basis of above the Company is required to clarify following: 1. Diluted earnings per share pursuant to issue of equity shares on exercise of options. 2. Subsequent changes or cancellation or exercise of such options; 3. Brief details of significant terms; 4. Variation of terms of options 5. Options lapsed; 6. The total number of shares arising as a result of exercise of option; 7. Money realized by exercise of options; 8. Options exercised; 9. Time within which option may be exercised; 10. Options vested; 11. Pricing formula; 12. Total number of shares covered by these options; 13. Whether the scheme is in terms of SEBI (SBEB) Regulations, 2014 (if applicable); 14. Brief details of options granted The response of the Company is awaited.
Feb 2019
1 Feb · Legal
Exchange has sought clarification from Bliss GVS Pharma Limited with respect to announcement dated 30-Jan-2019, Outcome of Board Meeting held on January 29, 2019.". On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment)The response of the Company is awaited.
Jan 2018
22 Jan · Legal
Exchange has sought clarification from Bliss GVS Pharma Limited with respect to announcement dated 19-Jan-2018, regarding " Outcome of Board Meeting held on January 19, 2018.".On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment);The response of the Company is awaited.
Jul 2016
May 2015
30 May · Legal
Exchange has sought clarification from Bliss GVS Pharma Limited with respect to announcement vide letter dated May 29, 2015 wherein "the Board has considered and approved Sale of Step Down subsidiary "Surgimed Pharma Limited" located at Kenya". On basis of above Company is required to clarify : 1. The amount and percentage of the turnover or revenue or income and net worth contributed by such entity during the last financial year. 2. The Expected date of Completion. 3. Rational. The reply from the Company is awaited.